Cellectis Sa Stock Current Liabilities
| CLLS Stock | USD 1.87 0.01 0.54% |
Cellectis SA fundamentals help investors to digest information that contributes to Cellectis' financial success or failures. It also enables traders to predict the movement of Cellectis Stock. The fundamental analysis module provides a way to measure Cellectis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cellectis stock.
Total Current Liabilities is likely to gain to about 162.9 M in 2024. Non Current Liabilities Total is likely to gain to about 99.2 M in 2024. Cellectis | Current Liabilities |
Cellectis SA Company Current Liabilities Analysis
Cellectis' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Cellectis Current Liabilities | 26.28 M |
Most of Cellectis' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectis SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cellectis Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Cellectis is extremely important. It helps to project a fair market value of Cellectis Stock properly, considering its historical fundamentals such as Current Liabilities. Since Cellectis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectis' interrelated accounts and indicators.
Click cells to compare fundamentals
Cellectis Current Liabilities Historical Pattern
Today, most investors in Cellectis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cellectis' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cellectis current liabilities as a starting point in their analysis.
Cellectis Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Cellectis Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Cellectis SA has a Current Liabilities of 26.28 M. This is 98.5% lower than that of the Biotechnology sector and 95.16% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.67% higher than that of the company.
Cellectis Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectis' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics of similar companies.Cellectis is currently under evaluation in current liabilities category among its peers.
Cellectis Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cellectis from analyzing Cellectis' financial statements. These drivers represent accounts that assess Cellectis' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cellectis' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 745.4M | 1.3B | 379.2M | 96.8M | 160.4M | 152.3M | |
| Enterprise Value | 432.1M | 1.1B | 295.3M | 82.0M | 108.7M | 103.3M |
Cellectis Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.34) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 11.48 M | ||||
| Shares Outstanding | 100.09 M | ||||
| Shares Owned By Insiders | 3.86 % | ||||
| Shares Owned By Institutions | 14.60 % | ||||
| Number Of Shares Shorted | 156.19 K | ||||
| Price To Earning | (14.84) X | ||||
| Price To Book | 1.45 X | ||||
| Price To Sales | 5.19 X | ||||
| Revenue | 755 K | ||||
| Gross Profit | 23.95 M | ||||
| EBITDA | (98.09 M) | ||||
| Net Income | (116.83 M) | ||||
| Cash And Equivalents | 153.13 M | ||||
| Cash Per Share | 3.37 X | ||||
| Total Debt | 92.85 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 1.29 X | ||||
| Cash Flow From Operations | (24.75 M) | ||||
| Short Ratio | 3.28 X | ||||
| Earnings Per Share | (1.16) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 216 | ||||
| Beta | 3.2 | ||||
| Market Capitalization | 187.18 M | ||||
| Total Asset | 334.27 M | ||||
| Retained Earnings | (405.76 M) | ||||
| Working Capital | 77.86 M | ||||
| Current Asset | 51 M | ||||
| Current Liabilities | 26.28 M | ||||
| Net Asset | 334.27 M |
About Cellectis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectis SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.